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Abstract This study was undertaken to determine the role of
tyrosine kinase on intracellular Ca2+ ([Ca2+]i), myosin light
chain (MLC) phosphorylation, and contraction caused by
norepinephrine (NE) in rat aorta. NE induced a sustained
contraction with an increase of [Ca2+]i. On the other hand, NE
increased the phosphorylation of the 20 kDa MLC transiently.
Pretreatment with genistein and tyrphostin 25, tyrosine kinase
inhibitors, significantly inhibited NE-induced contraction, but did
not affect the increase of [Ca2+]i and MLC phosphorylation.
These results suggest that tyrosine kinase may regulate the
NE-mediated contraction without altering [Ca2+]i and MLC
phosphorylation in rat aorta. ß 2002 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Calcium- and calmodulin-dependent phosphorylation of the
20 kDa myosin light chain (MLC) has been clearly shown to
be a major regulatory step in the activation of smooth muscle
contraction [1]. However, because stimulation-induced MLC
phosphorylation levels are increased only transiently while
force is maintained, additional regulatory pathways have
been proposed to account for the maintenance of muscular
force [2^4].
Previous studies using guinea-pig taenia coli, rat aorta, and
pulmonary artery suggest that there is communication be-
tween the tyrosine kinase pathway and the MLC kinase path-
way [5,6], which may in£uence smooth muscle contraction.
Indeed, involvement of tyrosine kinase was suggested recently
as a possible mechanism for agonist-induced vascular smooth
muscle contraction [7^11]. The proposed mechanism involves
the phosphorylation of protein on tyrosine residues by tyro-
sine kinase, which thereby contributes to signaling processes
and leads to muscle contraction.
Tyrosine kinase inhibitors have become widely used in cell
biology experiments as probes for tyrosine kinase activity and
they are also being considered as potential antiproliferative
chemotherapeutic agents [12]. Genistein and other putative
tyrosine kinase inhibitors decrease agonist-induced contrac-
tion in several types of smooth muscle, but have little e¡ect
on intact vessels stimulated by high K or on the Ca2-in-
duced contractions in L-escin-skinned microvessels [10].
There is evidence that tyrosine kinase participates in the
regulation of Ca2 entry associated with agonist-induced con-
traction in smooth muscle cells [13]. It has been reported that
genistein attenuates the agonist-induced increase in cytosolic
Ca2 concentration in smooth muscle cells from porcine cor-
onary artery and in A7r5 vascular smooth muscle cells [14,15].
Furthermore, some tyrosine kinase inhibitors are also re-
ported to decrease calcium channel currents [16]. The pathway
leading to Ca2 entry probably involves tyrosine kinase and
protein kinase C [17]. Thus, phosphorylation of tyrosine is
thought to be linked to transplasmalemmal Ca2 in£ux and
to regulate smooth muscle contraction. Genistein also de-
creased the Ca2 sensitivity of the force generated in ago-
nist-stimulated, K-toxin-skinned smooth muscle [18], as well
as in small mesenteric resistance arteries of the rat aorta [17].
However, in the intact, histamine-stimulated, swine carotid
artery, the inhibitory action of genistein on force was second-
ary to its attenuation of increases in intracellular Ca2
([Ca2]i), without any concomitant change in the [Ca2]i sen-
sitivity of myosin phosphorylation or force [19]. In uterine
smooth muscle, extracellular Ca2-independent contraction
was inhibited by genistein [20]. Taken together, these results
indicate that the vasodilating mechanism of tyrosine kinase
inhibitors on smooth muscle contraction is still not clari¢ed.
We used genistein and tyrphostin 25, putative tyrosine ki-
nase inhibitors, to evaluate the role of tyrosine kinase on the
contraction, [Ca2]i, and MLC phosphorylation caused by the
K1-adrenoceptor agonist, norepinephrine (NE), in rat thoracic
aorta.
2. Materials and methods
2.1. Materials
The following drugs were used in the present study. The monoclo-
nal antibody (mouse IgM) to myosin (20 kDa light chain) was ob-
tained from Sigma Chemicals (St. Louis, MO, USA). Horseradish
peroxidase-conjugated secondary antibody, rainbow protein molecu-
lar weight marker, enhanced chemiluminescence (ECL) reagent kit,
and ECL X-ray ¢lm were purchased from Amersham Life Science
(Little Chalfont, Buckinghamshire, UK). Pharmacological reagents
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such as NE, genistein, tyrphostin 25, and other analytical chemicals
were obtained from Sigma Chemicals. The protein assay kit and pro-
tein standard (bovine serum albumin) were obtained from Bio-Rad
Laboratories (Richmond, CA, USA) and Sigma Chemicals, respec-
tively.
2.2. Tissue preparation and tension measurements
Adult male rats (Sprague^Dawley, 250^350 g) were killed by inha-
lation of 100% CO2. Thoracic aortae were isolated carefully and im-
mediately immersed in ice-cold physiological salt solution (PSS) of the
following composition (in mM): NaCl 136.9, KCl 5.4, NaHCO3 23.8,
glucose 5.5, CaCl2 1.5, MgCl2 1.0, and ethylenediaminetetraacetic
acid 0.01. Fat and connective tissues were cleaned o¡ the preparation.
Endothelium was removed by gently rubbing the intima with a cotton
swab to avoid the endothelium-dependent relaxation e¡ect of acetyl-
choline. Helical strips of thoracic aorta (2 mm in width and 10^12 mm
in length) were dissected.
Aortic strips were placed in Magnus chambers containing 7 ml of
PSS (pH 7.4), which was aerated continuously with 95% O2/5% CO2.
A passive tension of 1.0 g was applied initially to each aortic strip,
which was then allowed to equilibrate at 37‡C for 60 min. Following
equilibration, strip contraction was initiated by the addition of KCl-
PSS (65.4 mM KCl; made by substituting 60 mM NaCl in normal
PSS with equimolar KCl) in order to provide a reference force for
standardizing the experimental values [21]. Changes in muscle tension
were recorded isometrically using force displacement transducers con-
nected to a Gould polygraph (Cleveland, OH, USA).
2.3. MLC phosphorylation detection
Muscle strips were frozen rapidly in a slurry of dry ice with 10%
(w/v) trichloroacetic acid (TCA) and 10 mM dithiothreitol (DTT) in
acetone. After 1 h, strips were removed to air-dry at room temper-
ature. Dried strips were homogenized in a solution of 10% (w/v) TCA
and 10 mM DTT/H2O, and then the muscle homogenates were cen-
trifuged at 10 000 rpm for 1 min. Supernatant was removed and
water-saturated ethyl ether was added and mixed, before further cen-
trifugation. Supernatant was again removed to wash out TCA. Pro-
teins were extracted from centrifuged pellets in urea bu¡er (20 mM
Tris, 23 mM glycine, 8 M urea, 0.04% bromophenol blue, 10 mM
DTT; pH 8.6 at 20‡C). Protein concentration was determined by the
Bradford method (Bio-Rad protein assay kit), employing bovine se-
rum albumin (Sigma) as a standard and subjecting 10 Wg protein to
urea/glycerol gel electrophoresis. The unphosphorylated and phos-
phorylated forms of 20 kDa MLC extracted from the frozen muscle
strips were separated by urea/glycerol gel electrophoresis according to
the protocol of Walsh et al. [22]. Immunoblot analysis was performed
using monoclonal anti-myosin (light chain 20K) antibody (1:500). The
immunoreactive bands were visualized by ECL reagent, and the im-
ages were analyzed by densitometry using Scion imaging software
(NIH, Bethesda, MD, USA). All values are reported as mol Pi/mol
MLC, corresponding to phosphorylated MLC as a percentage of the
total of both the phosphorylated and unphosphorylated MLC.
2.4. Measurement of [Ca2]i in rat thoracic aorta
[Ca2]i was measured according to the method described by Kwon
et al. [23], using the £uorescent calcium indicator fura-2. Muscle strips
were exposed to the acetoxymethyl ester of fura-2 (fura-2/AM; 5 WM)
in the presence of 0.02% cremophor EL for 5^6 h at room temper-
ature. The muscle strips were then transferred to the muscle bath that
is part of the £uorimeter (CAF-100; Jasco, Tokyo, Japan). The
muscle strips were illuminated alternately (48 Hz) with 340 nm and
380 nm light. The light emitted from the muscle strips was collected
by a photomultiplier through a 500 nm ¢lter.
2.5. Statistical analysis
All data are expressed as the mean þ S.E.M. The unpaired Student’s
t-test was used to test for signi¢cant di¡erences between means, with
P6 0.05 considered to be statistically signi¢cant.
3. Results
NE (1 WM) induced sustained contraction of rat thoracic
aorta (Fig. 1B). On the other hand, NE (1 WM) increased the
phosphorylation of 20 kDa MLC only transiently. After 1 min
stimulation with NE (1 WM), the phosphorylation of 20 kDa
MLC was increased maximally from 0.195 þ 0.024 to
0.481 þ 0.151 mol Pi/mol MLC (n = 4). After 5 min stimula-
tion, phosphorylation was 0.417 þ 0.015 mol Pi/mol MLC
(n = 4), and after 30 min stimulation, it was 0.344 þ 0.071
mol Pi/mol MLC (n = 4).
Therefore, NE induced a transient increase in the phosphor-
ylation of 20 kDa MLC of rat thoracic aorta (Fig. 1A,B). The
maximal phosphorylation was observed at 1 min after NE
application and it gradually decreased with time. Pretreatment
with genistein and tyrphostin 25 (1036^1034 M) for 30 min
reduced the NE-induced contraction in a concentration-de-
pendent manner (Fig. 2). The IC50 values of genistein and
Fig. 1. A: Phosphorylation of MLC measured by immunoblotting
after urea^glycerol polyacrylamide gel electrophoresis. B: Time
course of 20 kDa MLC phosphorylation (n = 4), and smooth muscle
contraction (n = 5), induced by 1 WM NE in rat thoracic aorta.
Data are expressed as mean þ S.E.M.
Fig. 2. E¡ect of tyrosine kinase inhibitors on NE (1 WM)-induced
contraction in rat thoracic aorta. Rat thoracic aortic strips were
preincubated with 10 WM genistein or 30 WM tyrphostin 25 for 30
min prior to the addition of NE. The contractile responses were
evoked by adding NE for 30 min with or without tyrosine kinase
inhibitor. Data are expressed as mean þ S.E.M. (n = 5); ** or ## de-
notes signi¢cant di¡erences from control (P6 0.01).
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tyrphostin 25 for NE-induced contraction were 15.05 WM
(n = 5) and 54.95 WM (n = 5), respectively.
On the other hand, to evaluate the e¡ect of tyrosine kinase
inhibitor on the 20 kDa MLC phosphorylation induced by
NE, strips were preincubated in genistein (10 WM) or tyrphos-
tin 25 (30 WM) for 30 min prior to the addition of NE. It was
found that 10 WM genistein did not inhibit the 20 kDa MLC
phosphorylation induced by NE (Fig. 3A,B). 30 WM tyrphos-
tin 25 also did not inhibit the 20 kDa MLC phosphorylation
induced by NE (Fig. 4A,B).
Fig. 5 shows the changes in [Ca2]i with respect to the
contraction amplitude of the aortic strips. Pretreatment of
the strips with 10 WM genistein (58.83 þ 2.36% of high K-
induced Ca2, n = 6) for 30 min did not a¡ect the increase of
[Ca2]i induced by 1 WM NE (57.33 þ 4.16% of high K-in-
duced Ca2, n = 6). Pretreatment of the strips with 30 WM
tyrphostin 25 (57.80 þ 2.58% of high K-induced Ca2,
n = 5) for 30 min also did not a¡ect the increase of [Ca2]i
induced by 1 WM NE. However, 10 WM genistein signi¢cantly
diminished the amplitude of the sustained contraction evoked
by 1 WM NE from 106.83 þ 7.33% of high K-induced con-
traction (n = 6) to 61.83 þ 3.27% of high K-induced contrac-
tion (P6 0.01, n = 6). 30 WM tyrphostin 25 also signi¢cantly
diminished the amplitude of the sustained contraction evoked
by 1 WM NE to 61.00 þ 3.39% of high K-induced contraction
(P6 0.01, n = 5).
4. Discussion
K-Adrenoceptors have been shown to stimulate phosphoi-
nositide hydrolysis, leading to [Ca2]i release and protein ki-
nase C activation [24]. Yet in other tissues, contraction occurs
in the absence of an increase of [Ca2]i [25], implying an
alternative mechanism. The contractile response to NE has
been shown to involve two components: (i) a phasic response,
which can only be elicited once after removal of extracellular
Ca2, and (ii) a sustained response, which can be generated
repeatedly in the absence of extracellular Ca2 [26]. Two dif-
ferent contractile mechanisms may, therefore, contribute to
the overall response.
It is well known that the phosphorylation of the 20 kDa
MLC is not the sole determinant for smooth muscle contrac-
tion. In most cases, during stimulation, MLC phosphorylation
decreases to suprabasal levels although force is sustained.
Thus, force may be maintained by slowly cycling unphos-
phorylated myosin^actin cross-bridges [27]. In our data, the
sustained contraction was developed by NE, even though the
phosphorylation of MLC increased only transiently (Fig.
1A,B). Therefore, secondary mechanism(s) for smooth muscle
contraction may be involved in the development and/or main-
tenance of contractile tension.
On the other hand, it has been reported that the tyrosine
kinase inhibitors, genistein and tyrphostin, decreased agonist-
induced contraction in various tissues of di¡erent species,
thereby suggesting that tyrosine phosphorylation of some pro-
teins may play a role in agonist-induced contraction
[10,18,28^30].
Our data show that, when the two structurally di¡erent
tyrosine kinase inhibitors, genistein (10 WM) and tyrphostin
25 (30 WM), signi¢cantly reduce the amplitude of the contrac-
tion evoked by NE (Fig. 2), the same concentrations do not
produce any inhibitory e¡ect on NE-induced 20 kDa MLC
phosphorylation (Figs. 3A,B and 4A,B), and even on [Ca2]i
in rat aortic vascular smooth muscle (Fig. 5A^C).
In a recent study by Jin et al. [6], tyrosine kinase activation
Fig. 3. A: Phosphorylation of MLC measured by immunoblotting
after urea^glycerol polyacrylamide gel electrophoresis. B: E¡ect of
10 WM genistein (GS) on NE (1 WM)-induced MLC phosphorylation
in rat thoracic aorta. The rat thoracic aorta was pretreated with
10 WM genistein for 30 min prior to the addition of NE. MLC
phosphorylation was measured 30 min after the addition of NE
with or without genistein. Data are expressed as mean þ S.E.M.
(n = 4); ** denotes signi¢cant di¡erences from control (P6 0.01).
Fig. 4. A: Phosphorylation of MLC measured by immunoblotting
after urea^glycerol polyacrylamide gel electrophoresis. B: E¡ect of
30 WM tyrphostin 25 (Tyr) on NE (1 WM)-induced MLC phosphor-
ylation in rat thoracic aorta. The rat thoracic aorta was pretreated
with 30 WM tyrphostin 25 for 30 min prior to the addition of NE.
MLC phosphorylation was measured 30 min after the addition of
NE with or without tyrphostin 25. Data are expressed as mean þ
S.E.M. (n = 4); ** denotes signi¢cant di¡erences from control
(P6 0.01).
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has been shown to increase phosphorylation of MLC stimu-
lated with fetal calf serum in vascular smooth muscle. Tyro-
sine phosphorylation is involved in smooth muscle contrac-
tion by regulating the Ca2 sensitivity of the contractile
apparatus [18,31]. In the present study, the tyrosine kinase-
dependent pathway has also been clearly demonstrated not to
be involved in transmembranous [Ca2]i entry in rat thoracic
aorta.
The K1-adrenoceptor subtypes (K1A and K1B) increase the
Ca2 sensitivity of contractile elements, and the Ca2 sensiti-
zation produced by the K1A subtype receptor plays an impor-
tant role in contraction of rabbit thoracic aorta smooth
muscle [32]. It has also been reported that the K1A-adrenocep-
tor subtype activates mainly MLC kinase-independent path-
ways of the contractile mechanisms in rabbit vascular smooth
muscle [33]. Therefore, the sustained contraction induced by
NE could be due to an increase in [Ca2]i, an increase in Ca2
sensitivity of contractile elements, or a Ca2-independent
mechanism [34]. Taken together, these data suggest that tyro-
sine kinase may regulate the contraction by NE without mod-
i¢cation of [Ca2]i and MLC phosphorylation. It should also
be noted that, at the concentration used, genistein, a putative
tyrosine kinase inhibitor, did not inhibit other kinases linked
to the signal transduction that results in vascular smooth
muscle contraction, such as MLC kinase [10].
In conclusion, tyrosine kinase participates in NE-induced
contraction of rat aortic smooth muscle. Although this may
involve one or more steps in the signal transduction pathway,
the enzyme appears to have a role in mediating sustained
contraction and plays no role in certain other processes, in-
cluding those involving [Ca2]i and MLC phosphorylation.
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